Despite its attractiveness as a cancer target, MYC has been considered “undruggable” and remains outside reach of pharmacological regulation, mainly due to its nuclear localization, lack of a defined ligand-binding site, and large protein-protein interaction (PPI) surface26,27. The gene discussed is MYC; the disease is cancer.